We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Ovarian Reserve Tests Prove Poor Predictors of Fertility

By LabMedica International staff writers
Posted on 24 Oct 2017
Tests that measure a woman’s “ovarian reserve” to estimate how many more years of fertility she has have grown increasingly popular, yet despite the lack of evidence of their utility, biomarkers of ovarian reserve are being promoted as potential markers of reproductive potential.

Previous studies have correlated levels of the three hormones with the number of eggs a woman has in her ovaries, known as a measure known as “ovarian reserve.” Studies have suggested that information could be used to predict how well a woman will respond to in vitro fertilization. More...
But in recent years, as more women are delaying pregnancy until later ages, ovarian reserve tests have begun to be used as a way to test for future fertility.

Medical Scientists at the University of North Carolina, (Chapel Hill, NC, USA) carried out a prospective time-to-pregnancy cohort study (2008 to date of last follow-up in March 2016) of 981 women aged 30 to 44 years without a history of infertility who had been trying to conceive for three months or less, recruited from the local community. Their mean age was 33.3 ± 3.2 years; 77% were white; and 36% were overweight or obese. The primary outcomes were the cumulative probability of conception by six and 12 cycles of attempt and relative fecundability (probability of conception in a given menstrual cycle). Conception was defined as a positive pregnancy test result.

The scientists looked the early-follicular-phase serum level of antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary level of FSH. They found that after adjusting for age, body mass index, race, current smoking status, and recent hormonal contraceptive use, 84 women with low AMH values of less than 0.7 ng/mL did not have a significantly different predicted probability of conceiving by six cycles of attempt (65%) compared with 579 women with normal values (62%) or by 12 cycles of attempt (84% versus 75% respectively). The 83 women with high serum FSH values of greater than 10 mIU/mL did not have a significantly different predicted probability of conceiving after six cycles of attempt compared with 654 women with normal values. Similarly, women with high urinary FSH values of greater than 11.5 mIU/mg creatinine did not have a significantly different predicted probability of conceiving and Inhibin B levels were not associated with the probability of conceiving in a given cycle.

The authors concluded that among women aged 30 to 44 years without a history of infertility who had been trying to conceive for three months or less, biomarkers indicating diminished ovarian reserve compared with normal ovarian reserve were not associated with reduced fertility. The study was published on October 10, 2017, in the Journal of the American Medical Association.

Related Links:
University of North Carolina


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: The model combines digitized tumor histopathology, clinical variables, and a 42-gene molecular panel using AI to generate a unified recurrence risk prediction (Image Credit: Shutterstock)

Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing

Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.